Senexin C

• Description :

  Senexin C is a selective and orally active CDK8/19 inhibitor. Senexin C shows a strong tumor-enrichment pharmacokinetic (PK) profile and tumor-pharmacodynamic (PD) marker responses. Senexin C inhibits the growth of MV4-11 leukemia cells with good tolerability[1].

• CAS Number :

  [2375554-02-0]

• UNSPSC :

  12352005

• Target :

  CDK

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/senexin-c.html

• Purity :

  98.82

• Solubility :

  DMSO : 33.33 mg/mL (ultrasonic; warming; adjust pH to 2 with 1M HCl; heat to 160°C)

• Smiles :

  N#CC1=CC=C2N=CC=C(NCCC3=CC=C4C=C(C(N5CCN(C)CC5)=O)C=CC4=C3)C2=C1

• Molecular Formula :

  C28H27N5O

• Molecular Weight :

  449.55

• References & Citations :

  [1]Zhang L, et al. A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics. J Med Chem. 2022; 65 (4) :3420-3433.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  CDK19; CDK8